BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Anxiety and PTSD clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for anxiety disorders: 86 (70 sponsors; 17 newly posted in the last 180 days, 3 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 13.4, rank 51 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 2, Phase 2 14, Phase 3 13, Phase 4 2, N/A 54.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Otsuka Pharmaceutical Development & Commercialization, Inc. new entrant3P3 330
Intra-Cellular Therapies, Inc.4P2 2, P3 221
Beijing Union Pharmaceutical Factory Ltd3P3 2, P1 100
Definium Therapeutics US, Inc. DFTX2P3 200
Psicofarma, S.A. De C.V.1P3 100
Senseye, Inc.1P3 100
Sichuan Jishengtang Pharmaceutical Co., Ltd.1P3 100
Vanda Pharmaceuticals VNDA1P3 101
Deliberate Solutions Inc.3NA 301
HabitAware Inc.2NA 201
Myota GmbH2NA 200
Power Life Sciences Inc.2NA 200
Psyrin Inc.2NA 200
Reunion Neuroscience Inc2P2 201
Seaport Therapeutics SPTX2P2 202
7 Generation Games1EARLY_P1 100
A Thousand Colibris, S.L1NA 100
AbbVie ABBV1P2 100
Accexible1NA 100
Afasci Inc1P2 100
Appa Health1NA 100
AppliedVR Inc.1NA 100
Attune Neurosciences Inc new entrant1NA 110
Beneo-Institute1NA 100
Biomedical Discoveries and Neuroscientific Foundations LLC1NA 100

New-entrant sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc., Attune Neurosciences Inc.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Vanda Pharmaceuticals VNDANCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderSocial Anxiety Disorder (SAD)active not recruiting500
2027-01 est.P2Newleos Therapeutics, Inc.NCT07323784 A Study of NTX-1472 in Social Anxiety DisorderSocial Anxiety Disorder (SAD)recruiting100
2027-01 est.P2Synendos Therapeutics AGNCT07478744 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety DisorderGeneralized Anxiety Disorderrecruiting24
2027-02 est.P2RDC Clinical Pty LtdNCT07315516 Sleep and Stress StudySleep Disorder (Disorder); Stress; Anxietyrecruiting240

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2AbbVie ABBVNCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized AnxGeneralized Anxiety Disorder (GAD)recruiting315
2026-10 est.P3Senseye, Inc.NCT07280065 REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic ToolPTSD - Post Traumatic Stress Disorderrecruiting1900
2026-08-13P3Definium Therapeutics US, Inc. DFTXNCT06809595 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Generalized Anxiety Disorderactive not recruiting245
2026-07-31 est.P2Oui Therapeutics, Inc.NCT07316088 Determining the Potential for Efficacy of OTX-601 in Reducing PTSD SymptomsPTSD; Post Traumatic Stress Disorderactive not recruiting40
2026-07-15P3Definium Therapeutics US, Inc. DFTXNCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Generalized Anxiety Disorderactive not recruiting214
2026-06-30 est.P3Beijing Union Pharmaceutical Factory LtdNCT06243640 Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GADGeneralized Anxiety Disorderrecruiting504
2026-06-30 est.P3Beijing Union Pharmaceutical Factory LtdNCT06243614 Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GADGeneralized Anxiety Disorderrecruiting410
2026-06-14P2Reconnect LabsNCT06685965 A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep DisturbancesPosttraumatic Stress Disorder (PTSD); Sleep Disturbances and Insomniacompleted12
2026-06-12P2VistaGen Therapeutics, Inc. VTGNNCT06809179 A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With SSocial Anxiety Disordercompleted61
2026-05-25P2Ono Pharmaceutical Co., Ltd.NCT06805565 A Study of ONO-1110 in Patients With Social Anxiety DisorderSocial Anxiety Disorder (SAD)completed115

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "anxiety disorders"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.